This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
by Kanishka Das
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
biotechs
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
by Zacks Equity Research
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
biotechs medical messenger-rna vaccines
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
biotechnology biotechs medical pharmaceuticals
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
by Ahan Chakraborty
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
biotechnology biotechs medical pharmaceuticals
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
biotechnology biotechs medical pharmaceuticals
Intellia Stock Declines Around 55% in 3 Months: Here's Why
by Zacks Equity Research
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
biotechs
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
by Zacks Equity Research
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
biotechs medical pharmaceuticals
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
by Ahan Chakraborty
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
biotechnology biotechs medical pharmaceuticals
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
by Zacks Equity Research
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
biotechs